



Cancer: Linking Powerhouses to Suicidal Bags

Laia Martinez-Carreres[†], Anita Nasrallah[†] and Lluís Fajas^{}*

Cancer and Metabolism Laboratory, Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

Membrane-bound organelles are integrated into cellular networks and work together for a common goal: regulating cell metabolism, cell signaling pathways, cell fate, cellular maintenance, and pathogen defense. Many of these interactions are well established, but little is known about the interplay between mitochondria and lysosomes, and their deregulation in cancer. The present review focuses on the common signaling pathways of both organelles, as well as the processes in which they both physically interact, their changes under pathological conditions, and the impact on targeting those organelles for treating cancer.

OPEN ACCESS

Edited by:

Cristina Mammucari,
University of Padua, Italy

Reviewed by:

Valeria Poli,
University of Turin, Italy
Darren Boehning,
University of Texas Health Science
Center at Houston, United States
Manuela Côrte-Real,
University of Minho, Portugal

*Correspondence:

Lluís Fajas
lluis.fajas@unil.ch

[†]These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

Received: 16 June 2017

Accepted: 21 August 2017

Published: 06 September 2017

Citation:

Martinez-Carreres L, Nasrallah A and
Fajas L (2017) Cancer: Linking
Powerhouses
to Suicidal Bags.
Front. Oncol. 7:204.
doi: 10.3389/fonc.2017.00204

Keywords: cancer, mitochondria, lysosomes, mammalian target of rapamycin, Rab7, AMP-activated protein kinase, mitophagy, lysosomal membrane permeabilization

INTRODUCTION

Cancer is characterized by the unrestricted cellular growth and proliferation of abnormal cells. It exhibits properties of motility, invasion, angiogenesis, and metastasis. Recent studies identified diverse mechanisms of metabolic plasticity in cancer cells. These include increased glucose uptake in most tumors, elevated glycolytic intermediates, increased pentose phosphate pathway activities, increased glutamine catabolism, and increased use of lactate as a fuel in selective tumors (1).

According to the American Cancer Society, it is estimated that, in the US, almost 1.7 million new cases of cancer will be diagnosed in 2017. Mostly, general cancer treatments are limited to radiation, chemotherapy, and surgery. However, these treatments encounter non-specific distribution of chemotherapeutic agents, insufficient drug concentrations to reach the tumor, and restricted ability to survey therapeutic responses (2). More efforts are targeted to find new therapies to help overpass these obstacles. Subcellular targeting is beneficial for therapy in several scenarios (3): (1) basic organelle malfunctions could be targeted, making the process more selective; (2) the quantity of drug required could be significantly reduced because of its specificity, which eventually helps in decreasing side effects; and (3) most importantly, intracellular drug targeting may surpass dangerous drawbacks of drug actions in cancer therapy, i.e., multidrug resistance (4, 5).

In most of the mechanisms of cancer initiation and progression, different organelles are involved, especially mitochondria and lysosomes, for their relevance in energy homeostasis and cell death (6). The purpose of this review is to shed light on the roles of mitochondria and lysosomes in cancer, as well as them being prominent targets for cancer therapy.

THE ROLE OF MITOCHONDRIA IN CANCER

Mitochondria, also called “powerhouses” of cells, are double membrane organelles, with their own genome, thought to have been originated from an ancient symbiosis that resulted when a nucleated cell engulfed an aerobic prokaryote. Through evolution, mitochondria conserved only a small part of prokaryotic bacterial genes, including the ones encoding 13 proteins of the respiratory chain (7).

In this manner, mitochondria gained a central role in the regulation of metabolism, cell proliferation, and apoptosis, while many tasks were transmitted to the host cells (8).

Other than being cell's powerhouses, mitochondria function as signaling organelles. They coordinate distinct metabolic pathways, producing metabolites required for cell survival and proliferation (9). In fact, mitochondria are key players in the calcium-signaling pathway (10). When toxic stimuli damage the cell, mitochondria release pro-apoptotic molecules, such as cytochrome *c*, thus regulating cell death (11). Moreover, mitochondria are established as the major site of production of free radicals, which are major signaling molecules in the cell (12). Recently, it has been shown that mitochondrial metabolites do not only have intermediary roles in energy generation but can also promote regulatory effects on post-translational modifications of proteins (13), as well as affecting chromatin structure and function (14).

Multiple human diseases have been strongly associated with impaired mitochondrial homeostasis. These include liver and cardiovascular diseases, neurological and muscular disorders, seizures, susceptibility to infections, and cancer (15–18). In cancer, mitochondrial roles vary as a function of genetic and environmental differences, as well as the tissue-of-origin of the diverse types of cancer. The main mitochondrial processes contributing to tumorigenesis include mitochondrial biogenesis and mitophagy, fission and fusion dynamics, metabolism, oxidative stress, and cell death (19).

Compared to normal cells, cancer cells show many alterations in energy metabolism. In the 1920s, cancer metabolism studies commenced with Otto Warburg's observation: to produce energy, cancer cells rely less on mitochondrial respiration and more on glycolysis. Warburg hypothesized that mitochondria must be dysfunctional, taking into consideration that glycolysis gives a lot less energy as compared to mitochondrial respiration (20). However, other scientists believed that the reduced mitochondrial activity is due to higher glycolysis. In some cases, Warburg's proposal holds true. Nevertheless, there are reports showing that the mitochondrial function in cancer cells in some cases is intact, or mitochondrial biogenesis is increased (21).

Mitochondrial biogenesis could be described as the division and growth of pre-existing mitochondria. It is regulated at the transcriptional and post-transcriptional levels of gene expression (22). Regulating mitochondrial biogenesis is an attractive target of key oncogenic signaling pathways, since cancer cells induce it to increase ATP production for cellular proliferation. PGC-1 α , through its interactions with numerous transcription factors, is a central regulator of mitochondrial biogenesis (23). It portrays a dual effect on cancer viability. On the one hand, PGC-1 α acts as a tumor suppressor in some cancers, resulting in induced apoptosis upon overexpression. In human epithelial ovarian cancer, apoptosis was induced *via* the organized regulation of Bcl-2 and Bcl-2-associated X protein (BAX) expression by PGC-1 α (24). PGC-1 α is considered a tumor suppressor not only because it induces apoptosis but also because it has been found to suppress the metastatic abilities of tumor cells *via* the direct regulation of transcriptional machinery (25, 26). For example, PGC-1 α directly increases ID2 transcription that binds

to the transcription factor TCF4, rendering it inactive. This in turn leads to a downregulation in metastasis-related genes, such as integrins, that are able to influence metastasis and invasion (25). On the other hand, the ability of PGC-1 α in sustaining metabolic homeostasis can also promote cancer cell survival and tumor metastasis (27). In cancer cells, silencing PGC-1 α resulted in deferred invasive potential and weakened metastatic ability without affecting proliferation and tumor growth. Consistently, the transition from primary lung tumor cells to metastatic cancer cells was coupled with more dependence on mitochondrial respiration, *via* PGC-1 α , leading to an upregulation of PGC-1 β , ERR α , and NRF1, which are mitochondrial-related biogenesis genes (28).

Another key activator of mitochondrial biogenesis in cancer is *c-Myc*, a transcription factor regulating cell cycle, proliferation, metabolism and cell death. Studies have demonstrated that the loss or gain of *Myc* decreases or increases mitochondrial mass, respectively. This is due to the fact that over 400 mitochondrial genes are identified as targets of *c-Myc* (29). A third effector of mitochondrial biogenesis is mammalian target of rapamycin (mTOR). It controls mitochondrial gene expression through the activation of PGC-1 α /YY1 and represses the inhibitory 4E-BPs (eukaryotic translation initiation factor 4E-binding protein 1) that downregulates the translation of mitochondrial proteins (30).

During tumorigenesis, mitochondrial dynamics is very important. It determines the equilibrium between cell death programs and mitochondrial energy production. Several studies demonstrated, in cancer, an imbalance in mitochondrial fission and fusion activities, depicted in decreased fusion, and/or elevated fission that resulted in fragmented mitochondrial networks *via* the K-Ras-DRK1/2-Drp1 pathway (31, 32). Also, *c-Myc* affects mitochondrial dynamics by altering the expression of proteins implicated in the fission and fusion processes (33).

Furthermore, mitochondria have a tight relationship with the intrinsic (also called mitochondrial) apoptotic cell death program, since B-cell lymphoma-2 (BCL-2) family of proteins regulates the integrity of the outer mitochondrial membrane (OMM). Mainly two members of this family, BAX and Bcl-2-associated killer (BAK) can break the OMM in response to apoptotic stimuli. This releases apoptogenic factors from inside mitochondria, such as cytochrome *c*, inducing activation of caspases and subsequent cell death. In some cases, mitochondria can also participate in the extrinsic apoptotic pathway, which is initiated by cell membrane death receptors. For example, FAS receptor can truncate Bid protein, another member of the BCL-2 family, *via* caspase 8. Truncated Bid (tBid) can then translocate to mitochondria to induce apoptosis (34).

Mitochondrial morphology is a hallmark for apoptotic susceptibility. Even though fission and fusion do not regulate apoptosis *per se*, the generated mitochondrial morphology supports the interaction with pro-apoptotic Bcl-2 proteins. Thus, mitochondrial hyper-fragmentation causes resistance to apoptosis due to the inability of mitochondrial membranes to interact with pro-apoptotic proteins (35).

Mitochondria play major roles in metabolic reprogramming, including the synthesis of macromolecules and cellular survival (1). One mechanism by which cancer drives these alterations in

metabolism is limiting pyruvate utilization by the mitochondria. This is achieved by regulating pyruvate kinases such as PKM isoforms (36), as well as downregulating mitochondrial pyruvate carriers: MPC1 and MPC2 (37). Moreover, in some tumor types, mutations in the enzymes of the tricarboxylic acid (TCA) cycle render the mitochondria dysfunctional. Cells from such tumors use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This, in turn, leads to the major reprogramming of amino acid metabolism and lipid synthesis (38).

There are multiple levels at which both mitochondrial biology and tumorigenic signaling vastly intersect. First, cellular physiology and tumorigenesis are affected by direct signals from mitochondria. Metabolites generated by the mitochondrial pathways affect gene transcription through chromatin modification, and cytosolic signaling pathways (19). For example, the TCA cycle intermediate α -ketoglutarate (α -KG) is a co-substrate for many enzymes in the cytoplasm and nucleus, including families of chromatin-modifying ones. In the case of chromatin regulation, glutamine-derived α -KG contributes to TET-dependent demethylation reactions (38). Second, many mutations were identified as directly associated with cancer risk (39). Cancer can be caused by mutations in nuclear-encoding genes, such as electron transporter chain (ETC) genes. For example, patients suffering from paraganglioma often presents dysfunctions in succinate dehydrogenase (SDH). Mutations of the same complex have also been found in other cancers, such as gastrointestinal stromal cancer, breast cancer, or renal carcinomas. Other enzymes such as fumarate hydratase (FH) have also found to be mutated in other cancers. When the function of these enzymes is lost, the metabolic intermediates fumarate and succinate accumulate, which in turn function as oncometabolites when found in excess (40, 41). In addition, mitochondrial DNA mutations (amplifications, deletions, point mutations, etc.) have been associated with various cancers (42). For example, point mutations in MT-ND1 gene modify complex I activity, having an influence on the tumorigenic characteristics of cells. Finally, and in order to support tumorigenesis, classical oncogenic signaling pathways alter mitochondrial functions. These include the *c-Myc*, p53, mTOR, and *k-Ras* signaling pathways (19). In addition, a main function of mitochondria is synthesizing aspartate for nucleotide synthesis, inducing cellular proliferation (43).

Mitochondria are complex organelles affecting cancer at many levels: initiation, proliferation, survival, or metastasis. One type of the various organelles that communicate with mitochondria is lysosomes. Mainly, this crosstalk depends on mitochondrial stress and/or destabilization of lysosomal membranes (44).

THE ROLE OF LYSOSOMES IN CANCER

Also known as “suicidal bags,” lysosomes were first described in 1950s by Christian de Duve as membrane-enclosed vesicles containing hydrolases. Functioning as a digestive system, they are found in all eukaryotic cells, except for mature erythrocytes. The hydrolytic enzymes that they contain include proteases, nucleases, and lipases that can break down proteins, nucleic acids, and lipids, respectively, to their simplest subunits (45).

Lysosomes are formed when material from outside the cell is internalized in clathrin-coated endocytic vesicles forming early endosomes. Endosomal maturation occurs with the delivery of lysosomal acid hydrolases from the trans Golgi network, which contribute lowering of the internal pH to about 5.5. Late endosomes then mature into lysosomes as they acquire a full complement of acid hydrolases, which digest the molecules originally taken up by endocytosis, phagocytosis, and autophagy (46). Nevertheless, many investigations have proved that lysosomes are not only degradative organelles but also participate in metabolism of the entire cell at different levels, and their modifications can promote or repress cell proliferation.

On one hand, lysosomes undergo Ca^{2+} regulated exocytosis, which is secreting their content into the extracellular space, and repairing their damaged plasma membranes; when the plasma membrane is injured, lysosomes quickly move to the site of damage and fuse with the plasma membrane. This allows effective resealing (47). On the other hand, they can sense nutrient availability, which controls energy metabolism and mediates the starvation response (48). Zoncu et al. proposed that amino acids have to be detected in the lysosomal lumen, signaling to the Rag GTPases in a manner that is vacuolar H^{+} -ATPase (V-ATPase)-dependent. This is known as the “inside-out” mechanism (49). Leucine, among other amino acids, must accumulate in the lumen of the lysosome to trigger the central regulator of cellular and organismal growth, mammalian target of rapamycin complex I (mTORC1) (50). mTORC1 is recruited by Rag GTPases on the lysosomal surface in response to amino acids, the site of activation by Rheb (Ras homolog enriched in brain), when growth factor-stimulated PI3K–Akt signaling is on (51, 52). Upon amino acid and growth factors removal, Rag GTPases releases mTORC1, causing it to become cytoplasmic and inactive. In those conditions, the negative regulator of Rheb, tuberous sclerosis complex 2 (TSC2), is lysosomally localized. Thus, lysosomal proteins change depending on the nutrient status of the cells (53, 54).

Lysosomal biogenesis as well as autophagy is controlled by the main regulator of lysosomal genes, known as TFEB or transcription factor EB; when mTORC1 is active, TFEB remains inactive at the lysosomal membrane. Inactivated mTORC1 induces TFEB localization to the nucleus to activate lysosomal gene transcription (52, 55).

Since lysosomes also serve as platforms of activation of mTORC1, it is important to mention the dysregulation of this pathway in cancer. Indeed, mTORC1 regulates several anabolic processes that are critical for tumorigenesis: it promotes protein synthesis, aerobic glycolysis, *de novo* lipid synthesis, *de novo* nucleotide synthesis, and represses autophagy and lysosomal biogenesis (56–59). Genes that encode components of the PI3K–Akt–mTOR pathway are frequently mutated in cancer, but despite few mutations have been characterized in mTOR, many tumor types present mTOR hyperactivation, thus promoting tumorigenesis (60, 61).

In addition, lysosomal intracellular positioning is important for adhesion and motility (62), and important for mTOR signaling, autophagosome formation, and autophagosome-lysosome fusion, and changes depending on the nutrient availability. During starvation, mTORC1 activity is repressed, which

induces autophagosome formation. Starvation increases pH, causing lysosomes to cluster near the microtubule-organizing center (MTOC), facilitating autophagosome–lysosome fusion. Conversely, nutrient replenishment restores basal pH inducing lysosomal scattering, which brings lysosomal mTORC1 to the cell periphery and stimulates its activity by increasing its coupling to the gradient of signaling molecules emanating from the plasma membrane (63). Given that peripheral lysosomes inside the cell are responsible for cell adhesion and motility, targeting those lysosomes in cancer cells is also a good strategy for cancer treatment (62).

As de Duve already stated in the 1950s, lysosomal membrane permeabilization (LMP), consequently leading to the leakage of lysosomal content into the cytoplasm, induced what is known as “lysosomal cell death” (45, 64). Major players of this mechanism are lysosomal cathepsin proteases. They have apoptotic and/or necrotic features, depending on the cellular context and the extent of leakage occurring into the cytosol (65).

Lysosomes in cancer cells undergo major changes. In some cases, they have an increased volume and protease activity, along with an improved lysosomal protease secretion, as compared to lysosomes in normal cells. Thus, they become hyperactivated as a reaction to fulfill the needs of the challenging microenvironment of the tumorigenic cells (62). For example, they require the ingestion of huge amounts of adhesion molecules and extracellular matrix molecules, leading to an upregulation in exocytosis. Also, they have to move inside the cell to repair damaged membranes (66, 67). Recently, a correlation between lysosomal movement and tumor cell invasion was also established, which was induced by tumor microenvironment stimuli (68). In particular, acidic extracellular pH induced lysosomal movement toward the cell peripheries, successively leading to Cathepsin B exocytosis from the lysosomes. This eventually promoted protease-dependent tumor invasion (69, 70). *In vitro* studies with glioma cells have shown that inhibition of lysosomal exocytosis with vacuolin-1 is a good strategy for fighting against invasion in cancer (71).

As explained above, changes in the lysosomal compartment, in the presence of increased secretions of cysteine cathepsins, render these lysosomes pro-oncogenic. This results in an increased neoplastic progression, *via* proteolytic pathway initiation (72). Other than matrix remodeling, lysosomal role in degradation is crucial in tumorigenesis. This has been observed in reports revealing that specific intracellular cathepsin inhibitors are able to block collagen degradation, promoting tumor viability (73). However, cathepsins are also depicted as proteases with tumor suppressor abilities for their role in inducing cell death through LMP (74, 75).

Due to their role in cell death, autophagy, and deregulating metabolism, targeting lysosomes have a great therapeutic potential in cancer. Lysosomal proteins are indeed good targets for cancer treatment (76), such as lysosome-associated membrane protein 1 (LAMP-1). LAMP-1 is suggested to have a role in cell–cell adhesion and migration, since it was detected on the surface of highly metastatic cancer cells, particularly from colon cancer (77). V-ATPase is another significant lysosomal membrane protein participating in cancer. It functions as a pump of protons to create an acidic pH of lysosomes. Also, it regulates endocytotic

trafficking and affects the tumor microenvironment, by extruding protons into the extracellular matrix (78). Moreover, in tumor malignancy, V-ATPase participates not only in the dysregulation of lysosomal trafficking but also in mTORC1 activation and autophagy (79).

In addition, lysosomes are key players in cancer drug resistance. They can sequester cancer drugs into their acidic milieu, thus, blunting the drugs’ effects (80). This further proves that targeting lysosomes may be a promising new therapeutic strategy for cancer.

Since both organelles, mitochondria and lysosomes, share the power of majorly impacting the process of tumorigenesis, we will next further describe the main crosstalk between these two important organelles, shedding light on their interplay in cancer and their impact on cancer therapy.

THE MITOCHONDRIAL–LYSOSOMAL INTERPLAY IN CANCER

In cancer, several important changes occur in all the organelles. However, the interplay between mitochondria and lysosomes is of high importance, because both organelles can interact to promote, in some cases cell death and in others tumorigenesis. There are two processes in which mitochondria and lysosomes work together: the first is LMP, a process in which enzymes from lysosomes can induce mitochondrial death pathway, and the second is mitophagy, a process in which lysosomes can degrade mitochondria, resulting in cell survival or cell death. Other than these two processes, there are several common effectors that play important roles in both organelles, which are also affected in cancer.

Mitochondrial–Lysosomal Mechanisms Lysosomal Membrane Permeabilization

As mentioned above, LMP is a mechanism that induces two types of cell death: apoptosis induced by partial and selective LMP, and necrosis provoked by the complete disruption of lysosomes. One of the causes of apoptosis during LMP is the activation of caspases in the mitochondrial death pathway by mitochondrial outer membrane permeabilization (MOMP) (65).

Reactive oxygen species (ROS) and cathepsins are well-known mediators of LMP-triggered cell death (81). It has been reported that only cathepsin D in the cytoplasm is enough to induce MOMP and apoptosis in human fibroblasts. However, cathepsin D alone is not in all cases of LMP sufficient to induce cell death (65).

As shown in **Figure 1**, MOMP can be triggered by LMP in two manners: either Bid dependent or Bid independent. Bid is known as BH3-interacting-domain death agonist and belongs to the pro-apoptotic BH3-only Bcl-2 family. The Bid-dependent process occurs when Bid is cleaved by the active cathepsins at cytosolic pH (specially cathepsins B and D), after which Bid is capable to form pores at the OMM inducing MOMP and releasing cytochrome *c* from the mitochondria (81). Despite tBid is also known to activate BAX and BAK, in some cases, LMP can induce MOMP in a Bid-independent manner; cathepsins or




FIGURE 1 | From lysosomal membrane permeabilization (LMP) to cell death through mitochondrial outer membrane permeabilization (MOMP). LMP is a process in which intralysosomal content (mostly cathepsins but also ROS) is leaked to the cytoplasm. Massive disruption of lysosomes induces cell death by necrosis, but selective LMP can induce apoptosis by MOMP. Cathepsins can promote, on the one hand, the cleavage of the pro-apoptotic protein Bid; and on the other hand, the translocation of Bcl-2-associated killer (BAK) and BAX to the outer mitochondrial membrane (OMM) where they form pores. Truncated Bid (tBid) can itself form pores to the OMM but can also activate BAK/BAK. These two processes can induce apoptosis, *via* release of cytochrome *c* and in a caspase-dependent way or independently of caspases. A positive feedback loop exists given that caspases and cathepsins are also inducers of LMP.

stress stimuli can directly activate the proteins BAX and/or BAK (82, 83). After their activation and translocation to the mitochondria, BAX and BAK make pores at the OMM. This permits the translocation of numerous molecules bigger than 100 kDa, without inducing membrane rupture leading to apoptosis (84–86). Furthermore, cathepsin B has a major role in linking LMP to MOMP *via* the generation of lipid mediators, such as arachidonic acid that induces MOMP (87). Alternatively, other than ROS and cathepsins, there is a large list of agents capable of inducing this mitochondrial membrane permeabilization, such as sphingolipids, phospholipase A2, etc. (64). Some of these stimuli, like the pro-apoptotic proteins or caspases, are derived from mitochondria, suggesting that there is a positive feedback loop: mitochondrial damage also induces LMP (**Figure 1**).

In addition, the mechanism by which cathepsins are released from the lysosomes is not yet clear. There are three possible hypotheses: (i) through the rupture of the lysosomal membrane, (ii) through specific pores, or (iii) by special transporters. In an attempt to find which of the three hypotheses is valid, fluorescently labeled dextran molecules of different sizes were used. When inducing LMP, it was shown that only small molecules (size of 10 kDa) were released to the cytoplasm in most of the cells. In almost half of the cells, 40-kDa molecules were redistributed to the cytoplasm, and molecules larger than 70 kDa remained inside lysosomes. Based on the fact that cathepsins are relatively small proteins, around 40 kDa in size, it is inferred that cathepsins are among these released molecules. Furthermore, the low intralysosomal pH was maintained, suggesting that lysosomes were still active (88). However, it is still not enough to rule out any of the possible mechanisms.

Until now, several explanations may account for the higher vulnerability to LMP of cancer cell lysosomes. Since lysosomes are relatively large in cancer cells (89), one possibility would be that they are more prone to inducing cell death than lysosomes with normal sizes (90). Another possibility lies in the observation that cancer cells have higher metabolic rates. This is accompanied by an elevated turnover of proteins that contains iron, leading to iron accumulation in the lysosomes. Subsequently, these lysosomes will undergo an iron-mediated predisposition to a ROS-induced LMP (91). In other words, a characteristic of cancer cells is the increased levels of ROS, which is associated with an amplified release of cathepsins from the lysosomes. Since cancer cells appear to be more susceptible to LMP, its induction will eventually facilitate cancer cell death (92).

Autophagy and Mitophagy

Macroautophagy is a process in which intracellular proteins or organelles are degraded in the lysosomes. Degraded products are then released from lysosomes and recycled into biosynthetic and metabolic pathways. Through the elimination of those damaged components, autophagy basically provides quality control over proteins and organelles, as well as sustains mitochondrial metabolic function and energy homeostasis (93). More than 30 proteins coordinate the autophagic processes, generating autophagosomes from essentially all membrane sources from the cell. Autophagy-related genes (Atg) control the processes of autophagy. The products of Atg genes are regulated by nutrients (mTOR), energy [AMP-activated protein kinase (AMPK)], and stress [hypoxia-inducible factor (HIF)], which can turn the pathway on and off (94). Nevertheless, autophagy may also induce cell

death, known as autophagic cell death (ACD). This specifically occurs when chromatin condensation is absent (95).

Autophagy's role in cancer is still not clear. Some cancers are dependent on autophagy for survival and other cancers use autophagy as a mechanism of cell death. In some models, autophagy suppresses cancer initiation by evading the toxic accumulation of damaged organelles, specifically mitochondria. On the short run, this helps in limiting oxidative stress. On the long run, it restricts chronic tissue damage and oncogenic signaling. So, in this context, autophagy stimulation might help suppress and/or prevent cancer initiation. Though, other cancers depend on autophagy for survival. In order to fit the high metabolic needs of growth and proliferation, cancers (such as the pancreatic) use autophagy-mediated recycling to their own advantage (96). Hence, inhibiting autophagy in this case could be an insight for selective cancer therapy, since these tumors are more dependent on autophagy than normal tissues (93).

Degradation of entire organelles can also occur: mitophagy (mitochondria), reticulophagy (endoplasmic reticulum), lipophagy (lipid droplets), peroxophagy (peroxisomes), and xenophagy (microbes). Mitophagy or autophagy of mitochondria is required to eliminate dysfunctional mitochondria to maintain appropriate metabolic and cell survival signals (97). Here, we will focus only on mitophagy, a key process for the control of mitochondrial quality. It is of substantial importance for the normal development of cells and tissues. The most studied mechanism of mitophagy initiation involves the E3 ubiquitin ligase Parkin and the serine–threonine kinase PINK1 (PTEN-induced putative kinase 1). PINK1 is a mitophagy receptor found at the OMM that accumulates when mitochondria are damaged or undergo any stress leading to mitochondrial membrane potential loss. This PINK1 accumulation at the OMM recruits Parkin from the cytosol. Parkin ubiquitinates proteins at the OMM. These ubiquitinated proteins are recognized by p62, also known as Sequestrome 1 (SQSTM 1). P-62 binds to LC3/Atg8 and takes p62-containing aggregates to the autophagosome to be degraded (98).

In the recent years, the role of mitophagy in cancer has been extensively reviewed. Parkin is frequently genetically inactivated in cancer. Although certain cancers, such as sarcomas and uterine cancer, have amplifications in PARK2 gene, the majority of tumors with lesions in PARK2, including ovarian, breast, and lung cancers, harbor deletions or loss of function mutations. This is mainly because the PARK2 gene is found on a fragile location on chromosome 6 (99). Parkin has been evidenced to control cell cycle regulators, such as cyclin-dependent kinases (CDKs) and cyclins, promoting acceleration of cell cycle progression. It can also lead to the accumulation of damaged mitochondria and elevated ROS production, triggering DNA damage and tumorigenesis (100). In addition, PINK1 and Parkin can promote apoptosis through targeting and ubiquitinating anti-apoptotic Mcl-1 leading to degradation; they operate as molecular switches by dictating cell fate as a response to diverse cellular stresses (101, 102). However, mitophagy can happen in cancer cells without active Parkin, known as mitophagy-independent Parkin function. OMM proteins, such as FUNDC1, BNIP3, and NIX, are autophagy receptors, independently of ubiquitination. Furthermore, other factors such as the phospholipid cardiolipin

can induce mitophagy, as well as ubiquitin ligases, such as SMURF1 and MAPL (103–105).

During hypoxia, HIFs can induce mitophagy through the transcription of NIX and BNIP3. In addition to its transcriptional activation by HIF-1, FoxO3A, PPAR α , RB/E2Fs, NF- κ B, oncogenic Ras, and p53 also transcriptionally regulate BNIP3 (103), while NIX is transcriptionally regulated by HIF-1 and p53 (106, 107). Upon hypoxia or high oxidative phosphorylation, the small GTPase Rheb translocates to the OMM, where it can interact with BNIP3 and NIX to induce mitophagy, resulting in mTOR inactivation (108, 109). The role of BNIP3-dependent mitophagy in cancer presents some controversies. BNIP3-dependent mitophagy is required to limit mitochondrial mass and ROS levels in growing tumors; its loss leads to HIF-1 α -dependent increases in tumor growth and increased progression to metastasis (110). However, other studies show that BNIP3 has a pro-tumorigenic role; its inactivation reduced cell migration and its upregulation suppressed the mTOR/S6K1 pathway. It is hypothesized that the dual role of BNIP3 can be explained by alternative splicing or variable transcriptional regulation *via* transcription factor Sp3 (111, 112).

Contrary to BNIP3, the role of NIX and FUNDC1 in tumor progression remains relatively unknown, requiring further investigation. They can induce mitophagy under hypoxic conditions (113). However, their role in cancer mitophagy is still to be revealed (107).

Signaling Pathways Involved in the Mitochondria–Lysosomal Crosstalk

As shown in **Figure 2**, the master regulator of cell growth and metabolism mTORC1 and proteins of the same pathway are the main linkers of mitochondria and lysosomes. As described




FIGURE 2 | Mitochondria and lysosomes downstream mammalian target of rapamycin complex I (mTORC1). Under nutrient rich conditions, active mTORC1 can induce the transcription of different genes involved in mitochondrial function and biogenesis. At the same time, it can repress TFEB transcription factor, which is the main responsible for transcription of genes involved in lysosomal and mitochondrial biogenesis, autophagy, etc.

earlier, under nutrient-rich conditions, mTORC1 is activated at the lysosomal surface. mRNA translation of many genes occurs, *via* the activation and repression of S6K and 4E-BP1, respectively. Among the genes repressed by 4E-BP are TFAM, Complex I and Complex V of the mitochondria, regulating mitochondrial activity and biogenesis (114).

On the other hand, under starvation conditions, mTORC1 is inhibited and TFEB positively regulates the expression of lysosomal and autophagy genes, as well as the expression of PGC-1 α . PGC-1 α coactivates numerous biological programs in diverse tissues; it is a key regulator of lipid metabolism (115), but also it promotes mitochondrial biogenesis (30). Notably, TFEB activation can be induced by mitophagy as well, in an attempt to induce mitochondrial biogenesis after eliminating malfunctioning or damaged ones. The mechanism of TFEB activation by mitophagy is different than that under starvation conditions. Parkin promotes TFEB nuclear translocation, inducing lysosomal and mitochondrial biogenesis (98). In addition to that, upon energy depletion, AMPK is activated. AMPK serves as a fuel gage as it becomes active when ATP/AMP ratio is low, thus maintaining energy homeostasis (116). AMPK inhibits mTORC1 by the direct phosphorylation of Raptor, a molecule of the mTORC1 complex. This explains why AMPK has been considered as a tumor suppressor. AMPK activation is essential for increased mitochondrial biogenesis under glucose-limited conditions, since AMPK activation increases the expression of PGC-1 α and TFAM (117) (**Figure 2**).

When mTORC1 is active, there is an increase of mitochondrial biogenesis. This increase in mitochondrial biogenesis will result in a gain of ATP production capacity, a mandatory energy source for translation (114). By contrast, mitochondrial biogenesis induced by AMPK is an attempt to accelerate ATP generation, for restoring its level in favor of cell survival. This takes place under limiting nutrient availability or metabolic stress (118).

To further emphasize the link between mitochondria and lysosomes, it has been shown that mTOR not only binds to lysosomes (when mTORC1 is activated when amino acids are present) but it can also be associated with MOM. This is needed to integrate different stress signals that affect the function of mitochondria and regulate a checkpoint implicating p70S6K, one of the well-known targets of mTORC1 (119). Recent studies link mitochondrial dynamics to the equilibrium between nutrient supply and energy demand, suggesting variations in mitochondrial architecture as an adaptive mechanism to metabolic demands (120).


Another important regulator is Rab7, which belongs to the RAB family, a RAS-related group of GTP-binding proteins. This family of proteins includes important regulators of vesicle transportation and is localized in certain intracellular compartments (121). Numerous studies indicate that Rab7 plays major roles in controlling maturation of endosomes and transportation to lysosomes, as well as in phagocytosis, retromere regulation, cytoskeleton regulation, autophagy, and mitophagy (122, 123).

Normally, Rab7 is found on late endosomes and this acquisition is complemented by Rab5 loss, an early endosome marker. The switch from Rab5 to Rab7 is a process in which both proteins cooperate sequentially and dynamically. This determines Rab5 recruitment to early endosomes and Rab7 recruitment

and Rab5 loss at late endosomes (124–126). Late endosomes can fuse with lysosomes and other late endosomes, only if the Rab5 to Rab7 switch is accompanied by variations in fusion and tethering machinery. This allows direct contact in between organelles (127).

Other than being a marker of late endosomes, Rab7 is vital for mitophagy (**Figure 3**), as it is a downstream effector of Parkin (128). This occurs with the help of TBC1D15/17 and Fis1. The first protein belongs to the TBC family (Tre2/Bub2/Cdc16), having RabGAP functions (129, 130), while the latter is a fission protein with cytosolic N-terminal, bound to the OMM at its C-terminal (131, 132). In the absence or inactivity of TBC1D15, membranes that are labeled with LC3 excessively accumulate and lose their cargo orientation. In turn, membrane tubules are sent along microtubule tracks away from the mitochondria. Therefore, it is inferred that, during mitophagy, TBC1D15 binds to Fis1 and LC3 inducing Rab7 activity, which leads to the shaping of the autophagosomal isolation membrane. In fact, besides promoting microtubule-associated trafficking and autophagosomal membrane growth, the activity of Rab7 is affected by TBC1D15/17 activity, inducing autophagosomal membrane expansion to correctly surround the mitochondria (128). This indicates that, in case of Parkin-regulated mitophagy, Rab7 is essential for expanding LC3-labeled isolation membranes. Otherwise, inactive Rab7 might help in mediating the release of LC3-positive membranes from microtubules (133). The above-described model substantially differs from the well-known role of Rab7 in controlling autophagosome maturation and fusion with lysosomes (134, 135). In addition, it was shown an increase in the interaction between Rab7 and Mitofusin2 (MFN2), a mitochondrial fusion-related protein, as a response to starvation. This suggests the contribution of Rab7 during autophagosomal membrane maturation, as an adaptor protein used by MFN2 (136). Hence, Rab7 has a dual role in mitophagy, i.e., autophagosome formation and maturation.

As shown in **Figure 3**, this multifaceted small GTPase also participates in other important processes in the cell, such as in apoptosis and the activation of stress response pathways (137). One of these pathways is the mTORC1 pathway, through which mTORC1 moves toward a Rab7-containing compartment in the presence of amino acids (138). The direct interaction between Rab7 and mTOR has been proved by co-immunoprecipitation experiments (139). During bioenergetic stress, several groups showed a Rab7-dependent lysosomal crosstalk with apoptosis and its regulatory machinery, i.e., intramitochondrial recruitment of endolysosomes mediates apoptosis. As explained before, in the presence of growth factors, mTOR and AKT are activated initiating downstream signaling cascades. Under these conditions, nutrient transporter proteins facilitate the import of extracellular nutrients, supporting cellular bioenergetics by supplying the mitochondria with metabolic substrates. In this case, one important apoptotic mediator, cytochrome *c* is retained at the mitochondrial intermembrane. When there is nutrient starvation, these same signaling cascades are silenced, and genes are no longer transcribed. Existing transporters are trafficked to the lysosomes by Rab7, where they are degraded and removed from the cell. This decrease in cellular bioenergetics results in substrate limitation at the mitochondrial site, loss of homeostasis,



and cytochrome *c* release, eventually leading to apoptosis. This process can be rescued by inhibiting Rab7. For example, transporter proteins destined to enter the endocytic pathway and be trafficked to lysosomes for degradation, instead, are recycled and re-expressed on the cellular surface. As a result, extracellular nutrients are continually imported, and cellular bioenergetics is maintained, as well as mitochondrial homeostasis, in the absence of growth factors (140). In this case, Rab7 has a proapoptotic function, by limiting cell autonomous uptake of extracellular nutrients (141).

In cancer, the specific role of Rab7 is not fully understood. In the literature, Rab7 has been depicted as either a tumor suppressor (68, 141, 142) or a proto-oncogene (143–146), depending on tumor type, morphology, and metastatic and invasive abilities (122) (**Figure 3**). Particularly, synergy between HSP90 inhibition and Rab7 depletion decreases EGFR and Her2 levels, through proteasomal degradation, and promotes apoptosis, depicting

a proto-oncogenic role of Rab7 (147, 148). During melanoma development, Myc is activated, inducing Rab7 overexpression. Subsequently, Rab7 expression is downregulated to support the invasive and metastatic characteristics of melanoma (145). Moreover, the knockdown of Rab7 in prostate cancer cells led to the overexpression of *c-Met*, a protein involved in the promotion of cell invasion and metastasis (149).

In fact, since Rab7 is mainly accountable for intracellular trafficking, which is linked to the metastatic/invasive ability of tumors, and the degradation of many organelles and molecules, such as adhesion molecules and signaling receptors, it is a key regulator in governing cellular homeostasis. Certainly, Rab7 is a central molecule of cell survival, differentiation, and apoptosis. Current data suggest that the regulation of Rab7 expression and activity can reduce several pathologies, such as cancer (122). Of course, further work will be needed to investigate this possibility.

THERAPEUTIC APPROACHES IN CANCER TREATMENT

Cancer cells exhibit a significant number of metabolic alterations associated with mitochondria, lysosomes, and other sub-cellular organelles. These organelles exhibit a number of deregulations, which have been identified as potential drug targets for successful rational drug design and therapy. For their involvement in bioenergetics, redox balancing, and survival, targeting mitochondria for therapeutic benefits is already in practice to induce apoptotic cell death (150, 151). In addition, the advances in lysosome research have highlighted their importance for degradation, signaling pathways, and cell death in pathophysiological conditions; thus, targeting lysosomes has also been considered a new therapeutic strategy for cancer treatment (76).

In this review, we highlighted the interplay between lysosomes and mitochondria and its importance in cell fate. We propose that targeting this crosstalk between both organelles might be crucial for fighting cancer.

Inducing LMP

Indeed, many compounds are described to induce LMP and subsequent cell death in various human cancer cells and animal models but are not in clinical use (152, 153). Besides, little is known about the endogenous inhibitors preventing LMP and which mechanisms suppress lysosomal hydrolases in the cytoplasm of both, normal and cancer cells. Inducing LMP-dependent death could activate self-destructive processes in tumor cells, particularly if those cells were dependent on such inhibitors. Future investigations are needed to clarify if antagonists of LMP inducers may be useful synergistically with the current clinical treatments (64).

Interestingly, a minimally invasive anticancer modality called Photodynamic therapy (PDT) is able to induce LMP. PDT combines a drug (a photosensitizing agent) with a precise light wavelength, inducing ROS generation and killing tumor cells (154). The location where the photosensitizing agent is directed is very important, as it determines where the primary damage occurs. Usually photosensitizing agents accumulate either in mitochondria, inducing rapid apoptosis, or in lysosomes, inducing LMP and subsequent cell death (64). To date, PDT is used for treating or relieving the symptoms of non-small cell lung cancer patients and esophageal cancer patients. PDT still presents some limitations, since only tumors on the skin or just underneath it, or in internal organ linings and/or cavities can be treated with this technique. But it cannot be used for treating large tumors or metastasis (155–158).

Targeting Mitophagy

Targeting mitophagy as an approach to adjuvant chemotherapy has been already questioned by Chourasia et al. (107). They claim that the deletion or inhibition of Parkin and BNIP3 induces the Warburg effect, thus favoring tumorigenesis. Nevertheless, acute chemical inhibition of mitophagy is still an effective approach for advanced tumors that have switched to glycolytic metabolism but still depend on mitochondria for further metabolic purposes (107). Of course, this approach has still to be therapeutically tested.

Targeting Common Effectors between Mitochondria and Lysosomes

Other than targeting processes in which mitochondria and lysosomes are linked, inhibitors of their main common effectors, i.e., AMPK or mTOR have been already tested for cancer therapy. The role of AMPK in cancer cells is paradoxical. It can be a tumor suppressor, but can also promote tumorigenesis, stimulating cell survival in glucose-deficient situations and preserving metabolic homeostasis (117). Despite that, the use of the anti-diabetic drug Metformin, non-steroidal anti-inflammatory drugs, such as Aspirin, AICAR, and some natural products known to be AMPK activators, has shown to decrease tumorigenesis in animal models and cancer cell lines (159, 160). In addition, preclinical evidence suggests that Metformin appears to prevent the proliferation and growth of certain tumor types. There are currently more than 100 ongoing or clinical studies assessing the role of metformin in the therapy cancer (161, 162). It is well understood that metformin targets the mitochondrial complex I. However, it has been suggested that metformin could directly influence the V-ATPase activity of lysosomes (163), so this fact further supports the importance of lysosomal–mitochondrial link for cancer treatment.

Targeting mTOR may be crucial for cancer treatment not only for cell growth and proliferation but also for reversing the Warburg effect characteristic of tumor cells (164). At the molecular level, mTORC1 inhibition may induce mitochondrial biogenesis *via* PGC-1 α , as well as repression of transcription of mitochondrial genes *via* 4E-BP1 (114) depending on the model. mTORC1 inhibition induces lysosomal biogenesis and also initiates several feedback loops to upstream pathways, activation of which might be beneficial for the survival of tumor cells and metastasis. The best-known mTOR inhibitor is Rapamycin, which does not inhibit directly mTOR's kinase (catalytic) activity. Together with FKBP12, it binds specifically to mTORC1 (at high concentrations also to mTORC2). The binding occurs next to the kinase active site. Consequently, it can only inhibit a number of mTORC1 functions. Given this, and the importance of mTOR for cancer, several groups have developed other inhibitors to target mTOR's catalytic subunit (PP242, Torin 1 and 2, etc.). As reviewed by Xie and al., some mTOR inhibitors are already in clinical trials for treating cancer (165). Despite that, the utility of such inhibitors in oncology still appears to be limited, given that autophagy can be induced by mTOR inhibition, thus promoting cancer cell survival.

As reviewed above, RAB7 is a prominent target for cancer treatment (143). In addition, there are already drugs that target RAB7. It has been shown that liensinine, a major isoquinoline alkaloid that inhibits RAB7A recruitment to lysosomes, not autophagosomes. In this way, autophagy/mitophagy is impaired, enhancing the efficacy of chemotherapy in breast cancer cell lines (166).

Using Nanomedicine for Inducing Cell Death

Nanotechnology is the science of controlling matter, at the molecular level, to generate devices with new biological, physical, and/or chemical characteristics. It is in the spotlight of therapeutic

innovation. The use of nanomaterial is a particularly promising tool not only to improve the diagnosis but also to generate new cancer treatments and overcome the drawbacks of traditional therapies (167). In particular, the discovery of gold nanorods (GNRs) has provided a new method to induce apoptosis specifically in cancer cells, while posing a negligible impact on normal cells. They are able to induce apoptosis in cancer cells through lysosomal permeability, as indicated by cathepsin D release, and a decrease in mitochondrial membrane potential (168). These findings are promising for the further implementation of nanotechnology at the clinical practice.

CONCLUSION AND FUTURE PERSPECTIVES

Intracellular organelles, as thoroughly discussed, are the major players of cellular networks. Even though physical contact among these organelles was exhaustively described throughout the years, research is now shifting toward revealing the crosstalk of these entities on the signaling levels, as well as their physiological relevance. Mainly, organelle interactions are needed for metabolite exchange, and more interestingly, in membrane dynamics, intracellular organelle distribution, and the assembly of dynamic signaling platforms depending on cellular requirements.

In tumors, cells significantly display metabolic aberrations, associated directly or indirectly with mitochondria and lysosomes. These anomalies promote cancer cell growth and survival, while exhibiting distinctive properties that render cancer cells vulnerable to specific anticancer agents. In other words, the deregulation of these organelles in cancer cells as compared to their counterparts in healthy cells is a main reason for promising targeted drug therapy. Though substantial advancement has been made regarding elucidating the role of these anomalies in oncogenesis and chemotherapy-resistance, a better interpretation of the main pathophysiological differences between organelles of

normal and tumor cells can undoubtedly compliment the efforts to improve selective targeted anti-cancer agents.

Lysosomes and mitochondria have common regulators and can physically interact to maintain cell homeostasis or induce cell death. However, in cancer everything becomes a paradox; all of the processes in which lysosomes and mitochondria interact, except for LMP, and the common regulators (mTOR, AMPK, Rab7, etc.) present a dual role: on the one hand, they can promote tumorigenesis and, on the other hand, they can induce cell death. The relative contribution of these pathways would depend on tumor type, state, metastatic ability, microenvironment, metabolic reprogramming, etc. This reflects the importance of these two organelles for cancer treatment. New potential targets have been proposed, i.e., PGC-1 α , TFEB, Rab7, etc. However, will these targets overpass the problem of having a paradoxical role in cancer treatment? As we have seen already, every case needs to be studied independently, in order to predict whether the treatment would be beneficial or not. This is known as personalized medicine.

AUTHOR CONTRIBUTIONS

LC, AN, and LC discussed the ideas and wrote the paper.

ACKNOWLEDGMENT

We thank Albert Giralt Coll for the critical reading of the manuscript.

FUNDING

LC was supported by the University of Lausanne. LC and AN performed this work as part of their degree in the University of Lausanne's PhD Programme in Life Sciences, emphasis Cardiovascular and Metabolism.

REFERENCES

- Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab* (2016) 23:27–47. doi:10.1016/j.cmet.2015.12.006
- Drabu S, Khatri S, Babu S, Verma D. Nanotechnology: an introduction to future drug delivery system. *J Chem Pharm Res* (2010) 2(1):444–57.
- Sakhrani NM, Padh H. Organelle targeting: third level of drug targeting. *Drug Des Devel Ther* (2013) 7:585–99. doi:10.2147/DDDT.S45614
- Cheng SM, Boddapati SV, D'Souza G, Weissig V. DQAsomes as mitochondria-targeted nanocarriers for anti-cancer drugs. *Nanotechnol Cancer Ther* (2006) 38:787–802. doi:10.1201/9781420006636.ch38
- Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. *Nat Rev Drug Discov* (2010) 9(1):29–42. doi:10.1038/nrd2897
- Flierl A, Jackson C, Cottrell B, Murdock D, Seibel P, Wallace DC. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. *Mol Ther* (2003) 7(4):550–7. doi:10.1016/S1525-0016(03)00037-6
- Antico Arciuch VG, Elguero ME, Poderoso JJ, Carreras MC. Mitochondrial regulation of cell cycle and proliferation. *Antioxid Redox Signal* (2012) 16(10):1150–80. doi:10.1089/ars.2011.4085
- Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. *Nat Rev Mol Cell Biol* (2007) 8:870–9. doi:10.1038/nrm2275
- Frezza C. Mitochondrial metabolites: undercover signalling molecules. *Interface Focus* (2017) 7:1–6. doi:10.1098/rsfs.2016.0100
- Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. *Nat Rev Mol Cell Biol* (2012) 13:566–78. doi:10.1038/nrm3412
- Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat Rev Mol Cell Biol* (2010) 11:621–32. doi:10.1038/nrm2952
- Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol* (2014) 24:453–62. doi:10.1016/j.cub.2014.03.034
- Menzies KJ, Zhang H, Katsyuba E, Auwerx J. Protein acetylation in metabolism – metabolites and cofactors. *Nat Rev Endocrinol* (2016) 12:43–60. doi:10.1038/nrendo.2015.181
- Sullivan LB, Gui DY, Heiden MG. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. *Nat Rev Cancer* (2016) 16:680–93. doi:10.1038/nrc.2016.85
- Arnoult D, Carneiro L, Tattoli I, Girardin SE. The role of mitochondria in cellular defense against microbial infection. *Semin Immunol* (2009) 21:223–32. doi:10.1016/j.smim.2009.05.009
- Fillano JJ, Goldenthal MJ, Rhodes CH, Marin-Garcia J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. *J Child Neurol* (2002) 17:435–9. doi:10.1177/088307380201700607

17. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. *Nature* (2012) 485:251–5. doi:10.1038/nature10992
18. Zsurka G, Kunz WS. Mitochondrial dysfunction and seizures: the neuronal energy crisis. *Lancet Neurol* (2015) 14:956–66. doi:10.1016/S1474-4422(15)00148-9
19. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. *Cell* (2016) 166:555–66. doi:10.1016/j.cell.2016.07.002
20. Warburg O. The metabolism of carcinoma cells. *J Cancer Res* (1925) 9:148–63. doi:10.1158/jcr.1925.148
21. Senyilmaz D, Teleman AA. Chicken or the egg: Warburg effect and mitochondrial dysfunction. *F1000Prime Rep* (2015) 7(41):1–13. doi:10.12703/P7-41
22. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. *Essays Biochem* (2010) 47:69–84. doi:10.1042/bse0470069
23. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* (1998) 92(6):829–39. doi:10.1016/S0092-8674(00)81410-5
24. Zhang Y, Ba Y, Liu C, Sun G, Ding L, Gao S, et al. PGC-1 α induces apoptosis in human epithelial ovarian cancer cells through a PPAR γ -dependent pathway. *Cell Res* (2007) 17(4):363–73. doi:10.1038/cr.2007.11
25. Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, et al. A PGC1 α -mediated transcriptional axis suppresses melanoma metastasis. *Nature* (2016) 537(7620):422–6. doi:10.1038/nature19347
26. Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosecvic J, Castillo-Martin M, et al. The metabolic co-regulator PGC1 α suppresses prostate cancer metastasis. *Nat Cell Biol* (2016) 18(6):645–56. doi:10.1038/ncb3357
27. Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z, et al. The role of PGC1 α in cancer metabolism and its therapeutic implications. *Mol Cancer Ther* (2016) 15:774–82. doi:10.1158/1535-7163.MCT-15-0621
28. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC1 α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nat Cell Biol* (2014) 16:992–1015. doi:10.1038/ncb3039
29. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, et al. Myc stimulates nuclear encoded mitochondrial genes and mitochondrial biogenesis. *Mol Cell Biol* (2005) 25:6225–34. doi:10.1128/MCB.25.14.6225-6234.2005
30. Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. *Cell Cycle* (2015) 14:473–80. doi:10.4161/15384101.2014.991572
31. Senft D, Ronai ZA. Regulators of mitochondrial dynamics in cancer. *Curr Opin Cell Biol* (2016) 39:43–52. doi:10.1016/j.cob.2016.02.001
32. Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Ascioia JJ, Yao JL, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. *Mol Cell* (2015) 51:521–36. doi:10.1016/j.molcel.2015.01.003
33. Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, et al. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. *PLoS One* (2012) 7(5):e37699. doi:10.1371/journal.pone.0037699
34. Wang C, Youle RJ. The role of mitochondria in apoptosis. *Annu Rev Genet* (2009) 43:95–119. doi:10.1146/annurev-genet-102108-134850
35. Renault TT, Floros KV, Elkholi R, Corrigan KA, Kushnareva Y, Wieder SY, et al. Mitochondrial shape governs BAX-induced membrane permeabilization and apoptosis. *Mol Cell* (2015) 57:69–82. doi:10.1016/j.molcel.2014.10.028
36. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* (2008) 452:230–3. doi:10.1038/nature06734
37. Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, et al. A role for the mitochondrial pyruvate carrier as a repressor of Warburg effect and colon cancer cell growth. *Mol Cell* (2014) 56:400–13. doi:10.1016/j.molcel.2014.09.026
38. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature* (2011) 481:385–8. doi:10.1038/nature10642
39. van Gisbergen MW, Voets AM, Starmans MH, de Coo IF, Yadak R, Hoffmann RF, et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. *Mutat Res Rev Mutat Res* (2015) 764:16–30. doi:10.1016/j.mrrrev.2015.01.001
40. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* (2009) 462:739–44. doi:10.1038/nature08617
41. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* (2010) 17:225–34. doi:10.1016/j.ccr.2010.01.020
42. Reznik E, Miller ML, Şenbabaoglu Y, Riaz N, Sarungbam J, Tickoo SK, et al. Mitochondrial DNA copy number variation across human cancers. *Elife* (2016) 5:1–20. doi:10.7554/eLife.10769
43. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. *Cell* (2015) 162(3):540–51. doi:10.1016/j.cell.2015.07.016
44. Aits S, Jaattela M. Lysosomal cell death at a glance. *J Cell Sci* (2013) 126:1905–12. doi:10.1242/jcs.091181
45. de Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmanns F. Tissue fractionation studies: intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J* (1955) 60(4):604–17. doi:10.1042/bj0600604
46. Cooper GM. *The Cell: A Molecular Approach*. Sunderland, MA: Sinauer Associates (2000).
47. Morgan AJ, Platt FM, Lloyd-Evans E, Galione A. Molecular mechanisms of endolysosomal Ca²⁺ signalling in health and disease. *Biochem J* (2011) 439(3):349–74. doi:10.1042/BJ20110949
48. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol* (2013) 14:283–96. doi:10.1038/nrm3565
49. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. *Science* (2011) 334(6056):678–83. doi:10.1126/science.1207056
50. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. *Trends Cell Biol* (2014) 24(7):400–6. doi:10.1016/j.tcb.2014.03.003
51. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. *Trends Cell Biol* (2015) 25(9):545–55. doi:10.1016/j.tcb.2015.06.002
52. Shimobayashi M, Hall MN. Multiple amino acid sensing inputs to mTORC1. *Cell Res* (2016) 26:7–20. doi:10.1038/cr.2015.146
53. Demetriades C, Doumpas N, Teleman AA. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. *Cell* (2014) 156(4):786–99. doi:10.1016/j.cell.2014.01.024
54. Zheng L, Zhang W, Zhou Y, Li F, Wei H, Peng J. Recent advances in understanding amino acid sensing mechanisms that regulate mTORC1. *Int J Mol Sci* (2016) 17(10):1635–50. doi:10.3390/ijms17101636
55. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. *Science* (2009) 325(5939):473–7. doi:10.1126/science.1174447
56. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. *Int J Mol Sci* (2012) 13(2):1886–918. doi:10.3390/ijms13021886
57. Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. *Nat Cell Biol* (2013) 15:555–64. doi:10.1038/ncb2763
58. Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. *Oncotarget* (2014) 5(1):49–66. doi:10.18632/oncotarget.1548
59. Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. *Am J Cancer Res* (2017) 7(3):383–404.
60. Tardy C, Codogno P, Autefage H, Levade H, Andrieu-Abadie N. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). *Biochim Biophys Acta* (2006) 1765(2):101–25. doi:10.1016/j.bbcan.2005.11.003
61. Alayev A, Holz MK. mTOR signaling for biological control and cancer. *J Cell Physiol* (2013) 228(8):1658–64. doi:10.1002/jcp.24351
62. Hämalistö S, Jäättelä M. Lysosomes in cancer—living on the edge (of the cell). *Curr Opin Cell Biol* (2016) 39:69–76. doi:10.1016/j.cob.2016.02.009
63. Korolchuk VI, Saiki S, Lichtenberg M, Siddiqui FH, Roberts EA, Imarisio S, et al. Lysosomal positioning coordinates cellular nutrient responses. *Nat Cell Biol* (2011) 13(4):453–60. doi:10.1038/ncb2204
64. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. *Oncogene* (2008) 27:6434–51. doi:10.1038/ncb2008.310

65. Kirkegaard T, Jäättelä M. Lysosomal involvement in cell death and cancer. *BBA Mol Cell Res* (2009) 1793(4):746–54. doi:10.1016/j.bbamcr.2008.09.008
66. Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? *Oncogene* (2013) 32:1995–2004. doi:10.1038/onc.2012.292
67. Xu H, Ren D. Lysosomal physiology. *Ann Rev Physiol* (2015) 77:57–80. doi:10.1146/annurev-physiol-021014-071649
68. Steffan JJ, Dykes SS, Coleman DT, Adams LK, Rogers D, Carroll JL, et al. Supporting a role for the GTPase Rab7 in prostate cancer progression. *PLoS One* (2014) 9(2):e87882. doi:10.1371/journal.pone.0087882
69. Friedl P, Wolf K. Tumor-cell invasion and migration: diversity and escape mechanisms. *Nat Rev Cancer* (2003) 3(5):362–74. doi:10.1038/nrc1075
70. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. *Cancer Res* (2008) 68(18):7247–9. doi:10.1158/0008-5472.CAN-08-0784
71. Liu Y, Zhou Y, Zhu K. Inhibition of glioma cell lysosome exocytosis inhibits glioma invasion. *PLoS One* (2012) 7:e45910. doi:10.1371/journal.pone.0045910
72. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. *Nat Rev Cancer* (2006) 6(10):764–75. doi:10.1038/nrc1949
73. Sameni M, Moin K, Sloane BF. Imaging proteolysis by living human breast cancer cells. *Neoplasia* (2000) 2:496–504. doi:10.1038/sj.neo.7900116
74. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. *Nat Rev Cancer* (2007) 7:800–8. doi:10.1038/nrc2228
75. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. *Oncogene* (2004) 23:2746–56. doi:10.1038/sj.onc.1207513
76. Piao S, Amaravadi RK. Targeting the lysosome in cancer. *Ann N Y Acad Sci* (2016) 1371(1):45–54. doi:10.1111/nyas.12953
77. Furuta K, Ikeda M, Nakayama Y, Nakamura K, Tanaka M, Hamasaki N, et al. Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases. *Am J Pathol* (2001) 159(2):449–55. doi:10.1016/S0002-9440(10)61716-6
78. Dettmer J, Hong-Hermesdorf A, Stierhof YD, Schumacher K. Vacuolar H⁺-ATPase activity is required for endocytic and secretory trafficking in arabidopsis. *Plant Cell* (2006) 18(3):715–30. doi:10.1105/tpc.105.037978
79. Meo-Evoli N, Almacellas E, Massucci FA, Gentilella A, Ambrosio S, Kozma SC, et al. V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagy. *Oncotarget* (2015) 6(29):28057–70. doi:10.18632/oncotarget.4812
80. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. *Clin Cancer Res* (2011) 17(23):7337–46. doi:10.1158/1078-0432.CCR-11-1667
81. Cirman T, Oresić K, Mazovec GD, Turk V, Reed JC, Myers RM, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. *J Biol Chem* (2004) 279(5):3578–87. doi:10.1074/jbc.M308347200
82. Kroemer G, Jäättelä M. Lysosomes and autophagy in cell death control. *Nat Rev Cancer* (2005) 5:886–97. doi:10.1038/nrc1738
83. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, et al. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. *J Exp Med* (2003) 197(10):1323–34. doi:10.1084/jem.20021952
84. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. *Mol Cell* (2005) 17(4):525–35. doi:10.1016/j.molcel.2005.02.003
85. Kägedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, et al. Lysosomal membrane permeabilization during apoptosis— involvement of Bax? *Int J Exp Pathol* (2005) 86(5):309–21. doi:10.1111/j.0959-9673.2005.00442.x
86. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. *Am J Physiol Gastrointest Liver Physiol* (2006) 290(6):G1339–46. doi:10.1152/ajpgi.00509.2005
87. Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes. *Nat Immunol* (2003) 4(5):416–23. doi:10.1038/ni0503-416
88. Bidère N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, et al. Cathepsin D triggers bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. *J Biol Chem* (2003) 278(33):31401–11. doi:10.1074/jbc.M301911200
89. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwala ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. *Neoplasia* (2003) 5(6):533–45. doi:10.1016/S1476-5586(03)80037-4
90. Ono K, Kim SO, Han J. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death. *Mol Cell Biol* (2003) 23(2):665–76. doi:10.1128/MCB.23.2.665-676.2003
91. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. *Free Radic Biol Med* (2002) 32(9):833–40. doi:10.1016/S0891-5849(02)00772-4
92. Gyrud-Hansen M, Nylandsted J, Jäättelä M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. *Cell Cycle* (2004) 3(12):1484–5. doi:10.4161/cc.3.12.1287
93. White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. *Clin Cancer Res* (2015) 21(22):5037–46. doi:10.1158/1078-0432.CCR-15-0490
94. Lorin S, Hamai A, Mehrpour M, Codogno P. Autophagy regulation and its role in cancer. *Semin Cancer Biol* (2013) 23:361–79. doi:10.1016/j.semcancer.2013.06.007
95. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. *Nat Rev Mol Cell Biol* (2008) 9(12):1004–10. doi:10.1038/nrm2529
96. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. *Genes Dev* (2011) 25(7):717–29. doi:10.1101/gad.2016111
97. Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. *Autophagy* (2007) 3(3):181–206. doi:10.4161/auto.3678
98. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem* (2007) 282(33):24131–45. doi:10.1074/jbc.M702824200
99. Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. *Nat Genet* (2014) 46:588–94. doi:10.1038/ng.2981
100. Palikaras K, Tavernarakis N. Measuring oxygen consumption rate in caenorhabditis elegans. *Bio Protoc* (2016) 6:23. doi:10.21203/BioProtoc.2049
101. Zhang C, Lee S, Peng Y, Bunker E, Giaime E, Shen J, et al. PINK1 triggers autocatalytic activation of parkin to specify cell fate decisions. *Curr Biol* (2014) 18(24):1854–65. doi:10.1016/j.cub.2014.07.014
102. Esteban-Martínez L, Doménech E, Boya P, Salazar-Roa M, Malumbres M. Mitophagy in mitosis: more than a myth. *Autophagy* (2015) 11(12):2379–80. doi:10.1080/15548627.2015.1108509
103. Chourasia AH, Macleod KF. Tumor suppressor functions of BNIP3 and mitophagy. *Autophagy* (2015) 11(10):1937–8. doi:10.1080/15548627.2015.1085136
104. Bernardini JP, Lazarou M, Dewson G. Parkin and mitophagy in cancer. *Oncogene* (2017) 36(10):1315–27. doi:10.1038/onc.2016.302
105. Drake LE, Springer MZ, Poole LP, Kim CJ, Macleod KF. Expanding perspectives on the significance of mitophagy in cancer. *Semin Cancer Biol* (2017) S1044-579X(17):30102–5. doi:10.1016/j.semcancer.2017.04.008
106. Palikaras K, Lionaki E, Tavernarakis N. Mitophagy: in sickness and in health. *Mol Cell Oncol* (2016) 3(1):1–2. doi:10.1080/23723556.2015.1056332
107. Chourasia AH, Boland ML, Macleod KF. Mitophagy and cancer. *Cancer Metab* (2015) 3(4):1–11. doi:10.1186/s40170-015-0130-8
108. Melder S, Chatelain EH, Lavie J, Mahfouf W, Jose C, Obre E, et al. Rheb regulates mitophagy induced by mitochondrial energetic status. *Cell Metab* (2013) 17(5):719–30. doi:10.1016/j.cmet.2013.03.014
109. Li Y, Wang Y, Kim E, Beemiller P, Wang CY, Swanson J, et al. Bnip3 mediates the hypoxia-induced inhibition on mTOR by interacting with Rheb. *J Biol Chem* (2007) 282(49):35803–13. doi:10.1074/jbc.M705231200
110. Palikaras K, Daskalakis I, Markaki M, Tavernarakis N. Mitophagy and age-related pathologies: development of new therapeutics by targeting mitochondrial turnover. *Pharmacol Ther* (2017). doi:10.1016/j.pharmthera.2017.04.005
111. Chang JY, Yi HS, Kim HW, Shong M. Dysregulation of mitophagy in carcinogenesis and tumor progression. *Biochim Biophys Acta* (2017) 1858(8):633–40. doi:10.1016/j.bbabi.2016.12.008

112. Huang Y, Shen P, Chen X, Chen Z, Zhao T, Chen N, et al. Transcriptional regulation of BNIP3 by Sp3 in prostate cancer. *Prostate* (2015) 75(14):1556–67. doi:10.1002/pros.23029
113. Kulikov AV, Luchkina EA, Gogvadze V, Zhivotovsky B. Mitophagy: link to cancer development and therapy. *Biochem Biophys Res Commun* (2017) 482(3):432–9. doi:10.1016/j.bbrc.2016.10.088
114. Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, et al. Mtorc1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. *Cell Metab* (2013) 18(5):698–711. doi:10.1016/j.cmet.2013.10.001
115. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. *Nat Cell Biol* (2013) 15(6):647–58. doi:10.1038/ncb2718
116. Hardie DG, Carling D. The AMP-activated protein kinase – fuel gauge of the mammalian cell? *Eur J Biochem* (1997) 246(2):259–73. doi:10.1111/j.1432-1033.1997.00259.x
117. Chaube B, Malvi P, Singh SV, Mohammad N, Violle B, Bhat MK. AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1ALPHA-mediated mitochondrial biogenesis. *Cell Death Discov* (2015) 1(15063):1–11. doi:10.1038/cddiscovery.2015.63
118. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab* (2005) 1(1):15–25. doi:10.1016/j.cmet.2004.12.003
119. Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. *Proc Natl Acad Sci U S A* (2002) 99(7):4319–24. doi:10.1073/pnas.261702698
120. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab* (2013) 17(4):491–506. doi:10.1016/j.cmet.2013.03.002
121. Agola JO, Jim PA, Ward HH, Basuray S, Wandering-Ness A. Rab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunities. *Clin Genet* (2011) 80(4):305–18. doi:10.1111/j.1399-0004.2011.01724.x
122. Guerra F, Bucci C. Multiple roles of the small GTPase Rab7. *Cells* (2016) 5(3):34–62. doi:10.3390/cells5030034
123. Zhang M, Chen L, Wang S, Wang T. Rab7: roles in membrane trafficking and disease. *Biosci Rep* (2009) 29(3):193–209. doi:10.1042/BSR20090032
124. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. *Cell* (2005) 122(5):735–49. doi:10.1016/j.cell.2005.06.043
125. Vonderheit A, Helenius A. Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes. *PLoS Biol* (2005) 3(7):e233. doi:10.1371/journal.pbio.0030233
126. Poteryaev D, Datta S, Ackema K, Zerial M, Spang A. Identification of the switch in early-to-late endosome transition. *Cell* (2010) 141(3):497–508. doi:10.1016/j.cell.2010.03.011
127. Luzzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. *Nat Rev Mol Cell Biol* (2007) 8:622–32. doi:10.1038/nrm2217
128. Yamano K, Fogel AI, Wang C, van der Blik AM, Youle RJ. Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy. *Elife* (2014) 3:1–24. doi:10.7554/eLife.01612
129. Frasa MA, Koessmeier KT, Ahmadian MR, Braga VM. Illuminating the functional and structural repertoire of human tbc/rabgaps. *Nat Rev Mol Cell Biol* (2013) 13(476):67–73. doi:10.1038/nrm3267
130. Fukuda M. Tbc proteins: GAPs for mammalian small GTPase Rab? *Biosci Rep* (2011) 31(3):159–68. doi:10.1042/BSR20100112
131. Mozdy AD, McCaffery JM, Shaw JM. Dnm1p GTPase-mediated mitochondrial fission is a multi-step process requiring the novel integral membrane component Fis1p. *J Cell Biol* (2000) 151(2):367–80. doi:10.1083/jcb.151.2.367
132. Suzuki M, Jeong SY, Karbowski M, Youle RJ, Tjandra N. The solution structure of human mitochondria fission protein Fis1 reveals a novel TPR-like helix bundle. *J Mol Biol* (2003) 334(3):445–58. doi:10.1016/j.jmb.2003.09.064
133. Pankiv S, Alemu EA, Brech A, Bruun JA, Lamark T, Overvatn A, et al. FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. *J Cell Biol* (2010) 188(2):253–69. doi:10.1083/jcb.200907015
134. Jager S, Bucci C, Tanida I, Ueno T, Kominami EL. Role for Rab7 in maturation of late autophagic vacuoles. *J Cell Sci* (2004) 117(20):4837–48. doi:10.1242/jcs.01370
135. Zhou J, Tan SH, Nicolas V, Bauvy C, Yang ND, Zhang J, et al. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. *Cell Res* (2013) 23(4):508–23. doi:10.1038/cr.2013.11
136. Zhao T, Huang X, Han L, Wang X, Cheng H, Zhao Y, et al. Central role of mitofusin 2 in autophagosome-lysosome fusion in cardiomyocytes. *J Biol Chem* (2012) 287(28):23615–25. doi:10.1074/jbc.M112.379164
137. Snider MD. A role for Rab7 GTPase in growth factor-regulated cell nutrition and apoptosis. *Mol Cell* (2003) 12(4):796–7. doi:10.1016/S1097-2765(03)00401-5
138. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Regulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* (2010) 141(2):290–303. doi:10.1016/j.cell.2010.02.024
139. Ding X, Zhang W, Zhao T, Yan C, Du H. Rab7 GTPase controls lipid metabolic signaling in myeloid-derived suppressor cells. *Oncotarget* (2017) 8(18):30123–37. doi:10.18632/oncotarget.16280
140. Edinger AL. Growth factors regulate cell survival by controlling nutrient transporter expression. *Biochem Soc Trans* (2005) 33(1):225–7. doi:10.1042/BSO330225
141. Edinger AL, Cinalli RM, Thompson CB. Rab7 prevents growth factor-independent survival by inhibiting cell-autonomous nutrient transporter expression. *Dev Cell* (2003) 5(4):571–82. doi:10.1016/S1534-5807(03)00291-0
142. Steffan JJ, Cardelli JA. Thiazolidinediones induce Rab7-RILP-MAPK-dependent juxtannuclear lysosome aggregation and reduce tumor cell invasion. *Traffic* (2010) 11(2):274–86. doi:10.1111/j.1600-0854.2009.01012.x
143. Wang T, Zhang M, Ma Z, Guo K, Tergaonkar V, Zeng Q, et al. A role of Rab7 in stabilizing EGFR-HER2 and in sustaining Akt survival signal. *J Cell Physiol* (2012) 227(6):2788–97. doi:10.1002/jcp.23023
144. Williams KC, Coppolino MG. Phosphorylation of membrane type 1-matrix metalloproteinase (mt1-mmp) and its vesicle-associated membrane protein 7 (Vamp7)-dependent trafficking facilitate cell invasion and migration. *J Biol Chem* (2011) 286(50):43405–16. doi:10.1074/jbc.M111.297069
145. Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, Cifdaloz M, Karras P, Osterloh L, et al. Rab7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. *Cancer Cell* (2014) 26(1):61–76. doi:10.1016/j.ccr.2014.04.030
146. Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. *Cancer Cell* (2005) 7(4):325–36. doi:10.1016/j.ccr.2005.03.024
147. Ceresa BP, Bahr SJ. Rab7 activity affects epidermal growth factor: epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. *J Biol Chem* (2006) 281(2):1099–106. doi:10.1074/jbc.M504175200
148. Sakane A, Hatakeyama S, Sasaki T. Involvement of Rab7 in EGF receptor degradation as an E3 ligase. *Biochem Biophys Res Commun* (2007) 357(4):1058–64. doi:10.1016/j.bbrc.2007.04.052
149. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. *J Cell Physiol* (2007) 213(2):316–25. doi:10.1002/jcp.21183
150. Ubah OC, Wallace HM. Cancer therapy: targeting mitochondria and other sub-cellular organelles. *Curr Pharm Des* (2014) 20:201–22. doi:10.2174/13816128113199990031
151. Wen S, Zhu D, Huang P. Targeting cancer cell mitochondria as a therapeutic approach. *Future Med Chem* (2013) 5(1):53–67. doi:10.4155/fmc.12.190
152. Rigo A, Vinante F. The anti-neoplastic agent α -bisabolol promotes cell death by inducing pores in mitochondria and lysosomes. *Apoptosis* (2016) 21(8):917–27. doi:10.1007/s10495-016-1257-y
153. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. *Proc Natl Acad Sci U S A* (2005) 102(1):192–7. doi:10.1073/pnas.0408592102
154. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. *Biochim Biophys Acta* (2007) 1776(1):86–107. doi:10.1016/j.bbcan.2007.07.001

155. Capella MA, Capella LS. A light in multidrug resistance: photodynamic treatment of multidrug-resistant tumors. *J Biomed Sci* (2003) 10(4):361–6. doi:10.1159/000071155
156. Vrouenraets MB, Visser GW, Snow GB, van Dongen GA. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. *Anticancer Res* (2003) 23(1B):505–22.
157. Gudgin Dickson EF, Goyan RL, Pottier RH. New directions in photodynamic therapy. *Cell Mol Biol* (2002) 48(8):939–54.
158. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. *J Natl Cancer Instit* (1998) 90(12):889–905. doi:10.1093/jnci/90.12.889
159. Li W, Saud SM, Young MR, Chen G, Hua B. Targeting AMPK for cancer prevention and treatment. *Oncotarget* (2015) 6(10):7365–78. doi:10.18632/oncotarget.3629
160. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. *Future Oncol* (2010) 6(3):457–70. doi:10.2217/fo.09.174
161. Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert B, et al. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. *PLoS Biol* (2015) 13(12):e1002309. doi:10.1371/journal.pbio.1002309
162. Kasznicki J, Sliwinska A, Drzewos J. Metformin in cancer prevention and therapy. *Ann Transl Med* (2014) 2(6):57–68. doi:10.3978/j.issn.2305-5839.2014.06.01
163. Kim J, You YJ. Regulation of organelle function by metformin. *IUBMB Life* (2017) 69(7):459–69. doi:10.1002/iub.1633
164. Lu CL, Qin L, Liu HC, Candas D, Fan M, Li JJ. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition – a Warbourg-Reversing effect. *PLoS One* (2015) 10(3):e0121046. doi:10.1371/journal.pone.0121046
165. Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. *F1000 Fac Rev* (2016) 5(2078):1–11. doi:10.12688/f1000research.9207.1
166. Zhou J, Li G, Zheng Y, Shen HM, Hu X, Ming QL, et al. A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission. *Autophagy* (2015) 11(8):1259–79. doi:10.1080/15548627.2015.1056970
167. Kodiha M, Wang YM, Hutter E, Maysinger D, Stochaj U. Off to the organelles – killing cancer cells with targeted gold nanoparticles. *Theranostics* (2015) 5(4):357–70. doi:10.7150/thno.10657
168. Zhang F, Zhu X, Gong J, Sun Y, Chen D, Wang J, et al. Lysosome-mitochondria-mediated apoptosis specifically evoked in cancer cells induced by gold nanorods. *Nanomedicine* (2016) 11(15):1993–2006. doi:10.2217/nmm-2016-0139

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Martinez-Carreres, Nasrallah and Fajas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.